Skip to main content
Premium Trial:

Request an Annual Quote

Lucira Health Molecular COVID/Flu Test Gets FDA Emergency Use Authorization

NEW YORK – The US Food and Drug Administration on Tuesday granted Emergency Use Authorization for a molecular COVID-19/flu test from Lucira Health.

The Lucira COVID-19 & Flu test was authorized for use at the point of care. According to the agency, it is the first molecular COVID-19 test to receive authorization following collaboration with the US National Institutes of Health's Independent Test Assessment Program (ITAP), which was created to speed up the regulatory review of over-the-counter COVID-19 tests.

The RT-LAMP-based test, developed by Emeryville, California-based Lucira, is for single use. It detects and differentiates between SARS-CoV-2, influenza A, and influenza B viral RNA in anterior nasal swab samples collected by a healthcare provider from individuals suspected of having COVID-19. The test is for use by CLIA-certified laboratories only.

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.